Courtney DiNardo, MD, MSCE, elaborated on interim phase II results regarding enasibenib plus azacitidine in patients with newly diagnosed acute myeloid leukemia, and the results from the QUAZAR trial.
Courtney DiNardo, MD, MSCE
Advertisement
Articles by Courtney DiNardo, MD, MSCE
Advertisement
Latest Updated Articles
Courtney DiNardo, MD, MSCE, on Enasidenib Plus Azacitidine in Newly Diagnosed AMLPublished: January 10th 2020 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma
2
HDP-101 Receives FDA Fast Track Designation in Multiple Myeloma
3
FDA Grants Priority Review to Enfortumab Vedotin Combo in MIBC Subset
4
Exa-Cel Improved HRQOL for in Transfusion-Dependent β-Thalassemia
5
